Update on nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Volumn 34, Issue 3, 2002, Pages 255-262

  McCullough, Arthur J ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hyperlipidemia; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Indexed keywords

DISEASE ASSOCIATION; FATTY LIVER; HUMAN; HYPERLIPIDEMIA; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY;

EID: 0036176194     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200203000-00013     Document Type: Review

References (119)

1. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease
2. Fatty liver hepatitis and cirrhosis in obese patients
3. Non-alcoholic steatohepatitis: A study of 49 patients
4. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
5. Nonalcoholic steatohepatitis: An expanded clinical entity
6. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
7. Non-alcoholic fatty liver disease: Assessment of variability in pathologic interpretations
8. Clinical features and natural history of non-alcoholic steatosis syndromes
9. Metabolic and nutritional considerations in nonalcoholic fatty liver
10. Non-alcoholic fatty liver (NASH syndrome)
11. Nonalcoholic steatohepatitis
12. Association of nonalcoholic fatty liver disease with insulin resistance
13. Liver pathology and the metabolic syndrome X in severe obesity
14. Prevalence of fatty liver in a general population of Okinawa, Japan
15. Liver and biliary ultrasonography in diabetic and non-diabetic obese women
16. The bright liver syndrome: Prevalence and determinants of a "bright" liver echo pattern
17. Prevalence of and risk factors for hepatic steatosis in northern Italy
18. Fatty infiltration of the liver: Analysis of prevalence, radiological and clinical features and influence on patient management
19. Liver histology in a "normal" population-examinations of 503 consecutive fatal traffic casualties
20. Liver pathology in aircrew
21. Trends in body weight and overweight in the U.S. population
22. Varying body mass index cut-off points to describe overweight prevalence among U.S. adults. NHANES III (1988-1994)
23. Obesity as a medical problem
24. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis
25. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis
26. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
27. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler
28. The natural history of non-alcoholic fatty liver: A follow-up study
29. Two cases from the spectrum of nonalcoholic steatohepatitis
30. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
31. Unsuspected cirrhosis discovered during obesity operations
32. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
33. Liver fibrosis in overweight patients
34. Steatohepatitis: A tale of two "hits"?
35. The ratio of aspartate amino transferase to alanine amino transferase: Potential value in differentiating non-alcoholic steatohepatitis from alcoholic liver disease
36. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
37. Hepatic iron and nonalcoholic fatty liver disease
38. Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology
39. Alcoholic liver disease
40. Alcohol-like liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury
41. Risk of fatty liver infiltration of cirrhosis of the liver in relation to ethanol consumption: A case-control study
42. Prediction of liver disease by alcohol intake, sex and age: A prospective population study
43. Factors determining cirrhosis in alcoholic liver disease
44. Excess weight as a risk factor for alcoholic liver disease
45. Drinking habits as co-factors of risk for alcohol induced liver damage
46. Body composition and hepatic steatosis as precursors for fibrotic liver disease
47. Idiopathic steatohepatitis in childhood: A multicenter retrospective study
48. Nonalcoholic steatohepatitis in children
49. Non-alcoholic steatohepatitis
50. Diagnosis and management of hemochromatosis
51. Nonalcoholic steatohepatitis: Association of insulin resistance
52. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome
53. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver
54. Mitochondrial adaptation to obesity-related oxidant stress
55. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
56. Alterations in liver ATP homeostasis in human non-alcoholic steatohepatitis. A pilot study
57. Hepatic steatosis: Innocent bystander or guilty party?
58. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
59. Cytokine expression in hepatocytes: Role of oxidative stress
60. Etiopathogenesis of non-alcoholic steatohepatitis
61. Mitochondria in steatohepatitis
62. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice
63. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
64. Changes in microsomal activity in alcoholism and obesity
65. Paroxysmal β-oxidation and steatohepatitis
66. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
67. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status
68. Comparison of serum concentrations of α-tocopherol and β-carotene in a cross-sectional sample of obese and non-obese children (NHANES III)
69. Nuclear migration of NF-KB correlates with TNF-α mRNA accumulation
70. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis
71. Withdrawal of life support, altruistic suicide, fratricidal killing, and euthanasia by lymphocytes: Different forms of drug-induced hepatic apoptosis
72. Activation of CPP32-like protease in tumor necrosis factor induced apoptosis is dependent on mitochondrial function
73. Stimulation of collagen α-(I) gene expression is associated with lipid peroxidation in hepatocellular injury: A link to tissue fibrosis?
74. Regulation of extracellular matrix synthesis by transforming growth factor β1 in human fat storing cells
75. Mallory body formation by ethanol feeding in drug induced mice
76. Identification of a transforming growth factor-β1/bone morphogenic protein 4 (TGF-β1/BMP4) response element within tissue transglutaminase gene promoter
77. Chemotactic activity of hydroxyalkenals on rat neutrophils
78. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines
79. Leptin deficiency enhances sensitivity to endotoxin-induced lethality
80. Animal models of steatosis
81. Oxidant stress in rat liver after lipo-polysaccharide administration: Effect of inducible nitric-oxide synthesis inhibition
82. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis
83. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth
84. Increased gastrointestinal production in obese mice: Implications for fatty liver disease pathogenesis
85. Tumor necrosis factor. A key concept of the obesity-diabetes link
86. The ob protein (leptin) pathway - A link between adipose tissue and central neural networks
87. Transdifferentiation of rat hepatic stellate cells results in leptin expression
88. Gender dependent alterations in serum leptin in alcoholic cirrhosis
89. Treatment of nonalcoholic fatty liver: Present and emerging therapies
90. Non-alcoholic steatohepatitis in obesity: A reversible condition
91. Effect of hepatitis morphology of treatment of obesity by fasting, reducing diets and small bowel bypass
92. Effect of weight reduction on hepatic abnormalities in overweight patients
93. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
94. Persistent hyperaminotranferasemia resolving after weight reduction in obese children
95. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population
96. Nonalcoholic steatohepatitis in children
97. Liver morphology and function tests in obesity and during total starvation
98. Hepatic effects of dietary weight loss in morbidly obese patients
99. Very low-calorie diets for the treatment of obesity
100. A risk benefit assessment of anti-obesity drugs
101. A pilot study of a thiazolidinedione, troglitazone in nonalcoholic steatohepatitis
102. Hepatic dysfunction associated with troglitazone
103. Hepatocellular injury in a patient receiving rosiglitazone
104. Metformin reverses fatty liver disease in obese, leptin-deficient mice
105. Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology
106. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
107. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study
108. Betaine for patients with nonalcoholic steatohepatitis: A promising new agent
109. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine
110. Role of tocopherols in the protection of biological systems against oxidative damage
111. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
112. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial
113. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis
114. Mechanism of hepatoprotective action of bile acids in liver disease
115. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of anti-oxidants
116. Study of human iso ursodeoxycholic acid metabolism
117. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
118. Bioavailability of four ursodeoxycholic acid preparations